Actively Recruiting
Evaluating a New Combination Therapy of Immune Checkpoint Inhibitors and Interferon Alpha to Achieve Functional Cure in Chronic Hepatitis B Infection
Led by The Second Affiliated Hospital of Chongqing Medical University · Updated on 2026-10-01
1200
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Chronic Hepatitis B virus HBV infection poses a significant public health challenge, especially in China. This trial explores a new treatment approach aiming for a functional cure, defined as sustained loss of the Hepatitis B surface antigen HBsAg. Current therapies achieve this in less than 10% of patients, but prior research with sequential interferon alpha IFN therapy following nucleostide analogues NAs treatment showed improved rates up to 30-50% in some patients. This study builds upon those results by combining immune checkpoint inhibitors with IFN to potentially enhance immune control and increase cure rates.
CONDITIONS
Brief Title
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)
Research Team
D
Dachuan Cai, MD
M
Min Chen, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here